Entry into a Material Definitive Agreement, Change in Directors or Pr
Item 1.01 Entry into a Material Definitive Agreement
On April 21, 2015, Ampio Pharmaceuticals, Inc., a Delaware corporation ("Ampio" or the "Company"), entered into a Voting Agreement (the "Agreement") with Rosewind Corporation (OTCMKTS:RSWN), a Colorado corporation ("Rosewind") which is expected to be renamed Aytu BioScience, Inc. in the near future. Pursuant to the Agreement, Ampio agreed to vote all of the shares of common stock of Rosewind beneficially owned by Ampio at a special meeting of Rosewind's stockholders or by written consent in favor of the following proposals approved by the Board of Directors of Rosewind and authorizing Rosewind to
(i) re-incorporate into the State of Delaware through a plan of conversion;
(2) effectuate a reverse stock split of Rosewind's common stock, at a ratio of one new share for every approximately 12.174 shares currently outstanding;
(3) change the name of Rosewind from "Rosewind Corporation" to "Aytu Bioscience, Inc."; and (4) approve a new stock option and incentive plan. The Agreement will remain in effect until Rosewind's stockholders approve the foregoing proposals. Ampio is the holder of approximately 81.5% of the common stock of Rosewind.
The description of the Agreement set forth herein does not purport to be complete and is qualified in its entirety by reference to the full text thereof, which is attached hereto as Exhibit 10.1.
Item 5.02 Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers
On April 16, 2015, Joshua R. Disbrow resigned as Chief Operating Officer of Ampio in connection with the Merger (as defined below) to assume the role of Chief Executive Officer of Rosewind, and Jarrett Disbrow resigned as President and Chief Executive Officer of Vyrix Pharmaceuticals, a Delaware corporation ("Vyrix"), and prior to the Merger a subsidiary of Ampio, to assume the role of Ch
It will probably drift down a bit. The real story will be the companies explanation for the saline failure and guidance as to when they can re-submit data. From what I have read there is no controversy about the efficacy of the drug, just the unexplained results from the saline injected control group.
Since there are no analysts following this stock I wonder who is going to downgrade them? You sound like someone fishing for cheap shares.
From the filing:
The Registrant’s common stock is currently quoted on the OTCQB, under the symbol “OCAT.” Upon commencement of trading on the NASDAQ Global Market on February 26, 2015, the Registrant’s common stock will be quoted under the symbol “OCAT.”
As of December 21st:
#2 in Top Apps (iPad) on Dec 21, 2014
#1 in Action Games (iPad) on Dec 21, 2014
#1 in Action Games (iPhone)
#1 in Action Games (iPad)
#1 in Family Games (iPad)
#2 in Family Games (iPhone)
#2 in Top Games (iPhone)
#2 in Kids Games (iPad)
#2 in Top Apps (iPad)
#2 in Top Games (iPad)
The beginning of the turnaround?
This is not our company but it is our industry....
After reviewing the information on Stemedica and Novastem, our family decided to give our father this opportunity. On December 8, Mr. Hockey underwent a two-day, non-surgical treatment at Novastem's medical facility. The treatment included neural stem cells injected into the spinal canal on Day 1 and mesenchymal stem cells by intravenous infusion on Day 2. His response was truly miraculous. At the end of Day 1 he was walking with minimal effort for the first time since his stroke. By Day 2 he was conversing comfortably with family and staff at the clinic.
On the third day, he walked to his seat on the plane under his own power. By Day 5 he was walking unaided and taking part in helping out with daily household chores. When tested, his ability to name items has gone from less than 25 percent before the procedure to 85 percent today. His physical therapists have been astonished.
As a family, we are thrilled that Dad's quality of life has greatly improved, and his progress has exceeded our greatest expectations. Once again, we cannot emphasize how much you have fueled Mr. Hockey's recovery and we thank everyone for their continued prayers and support."
Interesting to note that in the last few minutes the market maker COWN has appeared. This is Cowen & Company one of our investment firms for our secondary offering. Have never seen them as a market maker on OCAT/ACTC previously. Hmmmm! A short hedge or what? I have no idea. Positive note, NO Lincoln selling.
My personal opinion is that OCAT is indeed halted on NASDAQ but trading on the OTC. The Uplist is being threated as an IPO. Most IPO's do not start trading at the start of a business day. Remember Facebook from a couple of years ago. It was delayed a few times during the day and didn't start trading until after lunch. Filling the secondary offering just complicates things even more.
NASDAQ will not let OCAT trade until everything is in order. Hopefully that will be today.
Again from ACTionB InvestorStemCell
just got off the phone with jeffries and company "we are still gathering data points for a few investors are hoping to have this put together today, will pr as soon as it happens" asked if it was trading on nasdac or bb and he said he did not know the answer to that. he seemed busy and i did not want to take anymore time away from his business at hand…may the force be with us all….thats all i know